Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Thrombocythemia, Essential 1Prostatic Neoplasms 1Primary Myelofibrosis 1Polycythemia Vera 1Neoplasms, Plasma Cell 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid 1Leukemia 1

Interventions

fludarabine phosphate 16Cyclophosphamide 15Peripheral Blood Stem Cell Transplantation 10Tacrolimus 9Busulfan 9Whole-Body Irradiation 8Mycophenolic Acid 8fludarabine 6Methotrexate 6Cyclosporine 6Radiotherapy 5ruxolitinib 4Biopsy 4Antilymphocyte Serum 4Specimen Handling 3Decitabine 3peginterferon alfa-2a 2givinostat hydrochloride 2givinostat 2bomedemstat 2Stem Cell Transplantation 2Prednisone 2N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 2Methylprednisolone 2Melphalan 2Imatinib Mesylate 2Filgrastim 2Etoposide 2Cytarabine 2Aspirin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Thrombocythemia, Essential × lestaurtinib × Clear all
NCT00586651 2015-10-08

Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
39 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential

Data powered by HemOnc (CC BY 4.0) Colophon âš¡